Novonesis Lifts Guidance and Unlocks Shareholder Returns
Strong H1 2026 results prompt raised outlook, a €1B buyback, and a bolt-on acquisition in yeast.
NSIS-B.CO · Earnings Call · 2026-08-20
A First Half of Momentum
Novonesis delivered an 8% organic sales growth in the first half of 2026, with particularly strong performance in Food & Beverages (11% growth) and Household Care (12% in Q2). The company raised its full-year organic sales growth guidance to 7–8%, citing “strong 8% organic sales growth” — Ester Baiget, CEO · 2026-08-20 and a "good trajectory" for the rest of the year. The growth was broad-based, driven by adoption of innovation and sales synergies, with pricing contributing close to 2 percentage points. Adjusted EBITDA margin came in at 37.7% in H1, and management now expects to land at the higher end of the 37–38% range.Capital Allocation: A New Era
Perhaps the most notable change is the announcement of a €1 billion multi-year share buyback program, alongside an agreement to acquire the remaining 77% of MicroBioGen. CFO Rainer Lehmann explained that the buyback signals confidence in the temporary nature of elevated CapEx: “It's – we pointed out or I pointed out several times that the elevated CapEx is temporary, right? That's really the next 2 years.” — Rainer Lehmann, CFO · 2026-08-20 The MicroBioGen acquisition, described as a bolt on technology acquisition that expands yeast capabilities, is expected to be slightly accretive to margins, aligning with the company's allocation principle that prioritizes organic growth first, then bolt-ons, and now returns.The Tariff Refund and Global Context
Like many companies reporting this season, Novonesis is dealing with tariff considerations. The company noted that reimbursing U.S. tariffs to customers will be a drag on H2 organic growth (up to 40 bps) but is neutral to EBITDA. CFO Rainer Lehmann clarified: “There's no impact on the absolute number of the EBITDA in this regard.” — Rainer Lehmann, CFO · 2026-08-20 This resonates with a broader theme across retailers (TGT, LOW, WMT) and other industrials that have highlighted tariff refunds as a near-term headwind with no P&L impact.Addressing the "Too Good to Be True" Concern
Analysts pressed on the sustainability of such strong growth. CEO Ester Baiget was characteristically direct:She argued that the company's investments in R&D (10% of revenue), commercial resources, and capacity (like the West Allis plant) underpin durable growth. The company's track record of outgrowing end markets, driven by sales growth from penetration and innovation, supports this. Prior quarters also flagged cautious consumer behavior, but the company has consistently delivered. As Ester said in May: “Our direct exposure to Middle East and the sales in Middle East, they are small.” — Ester Baiget, CEO · 2026-05-05 reinforcing that they are well-diversified. The raised guidance and strategic moves from Novonesis are a clear signal that management sees a runway ahead, and the market's invested capital theme is being rewarded.Short answer, it is true. It is good and it is true.